Featured Research

from universities, journals, and other organizations

Initial Clinical Study Shows Safety And Bioactivity Of Cancer Vaccine

Date:
January 30, 2002
Source:
Duke University Medical Center
Summary:
A new phase I clinical trial of a prostate cancer vaccine developed at Duke University Medical Center has shown that the vaccine made from the patient's own dendritic cells causes no adverse side effects. More importantly, the trials indicate that the vaccine is able to boost the patient's immune system to fight cancer.

DURHAM, N.C. -- A new phase I clinical trial of a prostate cancer vaccine developed at Duke University Medical Center has shown that the vaccine made from the patient's own dendritic cells causes no adverse side effects. More importantly, the trials indicate that the vaccine is able to boost the patient's immune system to fight cancer.

Related Articles


The results of this trial in 13 patients are published in the February 2002 issue of the Journal of Clinical Investigations.

"This is the first study that has data on the safety and immunological efficacy of this type of cancer vaccine," said Dr. Johannes Vieweg, an associate professor of urology and assistant professor of immunology at Duke University Medical Center and senior investigator in the study. "And while this work was done in prostate cancer patients, we believe this method may prove to work in most cancers, not just prostate cancer."

Dendritic cells are white blood cells that activate the immune system by capturing antigens — substances that trigger an immune response, such as against a virus, bacteria or tumor — and presenting them to the body's killer cells, called "T cells." The vaccine created in the Duke study introduces genetic information from a prostate cancer patient's own dendritic cells, in the form of RNA from prostate-specific antigen (PSA). This antigen is secreted by the prostate gland and is elevated in some forms of prostate cancer. Once the dendritic cells use the RNA to produce and present the PSA antigen, they are injected back under the patient's skin and activate the T cells to attack tumors.

In the trial, 13 men with metastatic prostate cancer were given three escalating doses of the vaccine. Overall, the vaccine was well tolerated, reported Vieweg and his colleagues. Four subjects had low-grade fevers and flu-like symptoms, and four patients had inflammation at the site of the injection that subsided after two to three days. "Patients responded well to the vaccine because we are using materials from their own body to create a vaccine that is designed just for them," said Vieweg.

In the study, the researchers performed immunological tests to ensure that T cells were functioning and able to kill tumor cells, in addition to tests to determine whether the T cell levels rose. In all 13 participants, the researchers detected activation of PSA-specific T cell responses, suggesting the vaccine was successful in boosting the immune system and turning T cell attention to the cancer.

Vieweg said that the immunological data, which is sometimes not collected in such trials, is highly important in proving that the cancer vaccine is working in the patient and other influences are not at work.

"Some studies examine only if there is a reduction in tumor growth, but this would only show part of the story," he said. "You wouldn't see the subclinical changes in the body that might indicate that a vaccine is promising.

Immunological studies are time-consuming and complex, but extremely important when linking a cause-and-effect relationship between the vaccine and the data we collect. We often might not see a clinical regression of the tumor, but we might see signs that the vaccine is working in the immunological data. It's all about small steps."

The Duke study was not designed to track tumor regression because the small trial was aimed at determining only whether the vaccine was safe and effective in stimulating T cell response. However, the researchers tracked PSA levels in seven of the 13 patients. Six were excluded because they required radiation treatments for preexisting tumors or they took herbal supplements that could impact PSA levels. In the remaining seven, six had a significant decrease in PSA levels and three patients exhibited a decrease in free-circulating tumor cells detected in the blood.

According to Vieweg, the next step is to use fully mature dendritic cells and program them to carry multiple tumor antigens rather than just PSA. Vieweg cautioned that a possible side effect of a more potent vaccine might be that it could overactivate the immune system and cause T cells to attack healthy cells.

However, Vieweg said that if such a problem were to occur, it could be adjusted easily by withholding vaccine booster shots, changing the dose or changing the antigen.

The study was supported by grants from the National Institutes of Health, the CaP CURE Foundation, and the National Center for Research Resources.

Other authors of this study include: Axel Heiser, Doris Coleman, Dr. Jens Dannull, Donna Yancey, Margaret A. Maurice, Costas D. Lallas, Dr. Philipp Dahm, Donna Niedzwiecki and Eli Gilboa, all of Duke University Medical Center.


Story Source:

The above story is based on materials provided by Duke University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Duke University Medical Center. "Initial Clinical Study Shows Safety And Bioactivity Of Cancer Vaccine." ScienceDaily. ScienceDaily, 30 January 2002. <www.sciencedaily.com/releases/2002/01/020130073447.htm>.
Duke University Medical Center. (2002, January 30). Initial Clinical Study Shows Safety And Bioactivity Of Cancer Vaccine. ScienceDaily. Retrieved October 30, 2014 from www.sciencedaily.com/releases/2002/01/020130073447.htm
Duke University Medical Center. "Initial Clinical Study Shows Safety And Bioactivity Of Cancer Vaccine." ScienceDaily. www.sciencedaily.com/releases/2002/01/020130073447.htm (accessed October 30, 2014).

Share This



More Health & Medicine News

Thursday, October 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Mind-Controlled Prosthetic Arm Restores Amputee Dexterity

Reuters - Innovations Video Online (Oct. 29, 2014) A Swedish amputee who became the first person to ever receive a brain controlled prosthetic arm is able to manipulate and handle delicate objects with an unprecedented level of dexterity. The device is connected directly to his bone, nerves and muscles, giving him the ability to control it with his thoughts. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Google To Use Nanoparticles, Wearables To Detect Disease

Google To Use Nanoparticles, Wearables To Detect Disease

Newsy (Oct. 29, 2014) Google X wants to improve modern medicine with nanoparticles and a wearable device. It's all an attempt to tackle disease detection and prevention. Video provided by Newsy
Powered by NewsLook.com
Can Drinking Milk Lead To Early Death?

Can Drinking Milk Lead To Early Death?

Newsy (Oct. 29, 2014) Researchers in Sweden released a study showing heavy milk drinkers face an increased mortality risk from a variety of causes. Video provided by Newsy
Powered by NewsLook.com
Obama: The US Will Not 'run and Hide' From Ebola

Obama: The US Will Not 'run and Hide' From Ebola

AP (Oct. 29, 2014) Surrounded by health care workers in the White House East Room, President Barack Obama said the U.S. will likely see additional Ebola cases in the weeks ahead. But he said the nation can't seal itself off in the fight against the disease. (Oct. 29) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins